Toll样受体3通过保守的钙化机制介导主动脉瓣狭窄
研究探讨TLR3在钙化性主动脉瓣疾病中的作用,发现BGN是TLR3的内源性激动剂,通过TLR3-IFNAR1轴诱导瓣膜间质细胞成骨分化,动物模型和两个大型队列证实该通路与主动脉瓣狭窄相关。
要点
- BGN-TLR3-IFNAR1轴是驱动主动脉瓣钙化的进化保守通路
- BGN经XYLT1成熟后激活TLR3,诱导I型干扰素依赖的成骨分化
- Bgn-/-、Tlr3-/-和Ifnar1-/-小鼠均受保护免于CAVD且骨形成受损
核心结论
- BGN-TLR3-IFNAR1轴是调控主动脉瓣钙化的进化保守通路,可作为预防CAVD的潜在治疗靶点。
研究设计与样本
- 人主动脉瓣间质细胞接受机械牵张或合成TLR3激动剂处理,分析骨形成、基因表达和IFN信号通路。
- 使用多种抑制剂解析信号通路,筛选潜在脂质和蛋白聚糖作为TLR3配体,通过计算机建模和免疫共沉淀验证配体-受体相互作用。
- 使用Bgn、Tlr3和Ifnar1缺陷小鼠及特定斑马鱼模型研究BGN-TLR3-IFN轴在CAVD和骨形成中的作用。
- 在GERA队列(n=55 192,含3469例主动脉瓣狭窄)和UK Biobank队列(n=257 231,含2213例主动脉瓣狭窄)中检验BGN-TLR3-IFN通路基因变异与CAVD的关联。
主要发现
- TLR3是瓣膜间质细胞钙化的中心分子调节因子,BGN是TLR3新的内源性激动剂。
- XYLT1介导的BGN翻译后成熟是TLR3激活所必需的。
- BGN通过TLR3依赖的I型IFN诱导促进瓣膜间质细胞向成骨细胞转分化。
- Bgn-/-、Tlr3-/-和Ifnar1-/-小鼠受保护免于CAVD且骨形成受损。
- 对超过30万人的两个大型队列荟萃分析显示,XYLT1-BGN-TLR3-IFNAR1通路相关基因变异与人类CAVD相关。
临床怎么用
- BGN-TLR3-IFNAR1轴是预防CAVD的潜在治疗靶点,但尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Calcific aortic valve disease (CAVD) is characterized by a phenotypic switch of valvular interstitial cells to bone-forming cells. Toll-like receptors (TLRs) are evolutionarily conserved pattern recognition receptors at the interface between innate immunity and tissue repair. Type I interferons (IFNs) are not only crucial for an adequate antiviral response but also implicated in bone formation. We hypothesized that the accumulation of endogenous TLR3 ligands in the valvular leaflets may promote the generation of osteoblast-like cells through enhanced type I IFN signaling. METHODS: Human valvular interstitial cells isolated from aortic valves were challenged with mechanical strain or synthetic TLR3 agonists and analyzed for bone formation, gene expression profiles, and IFN signaling pathways. Different inhibitors were used to delineate the engaged signaling pathways. Moreover, we screened a variety of potential lipids and proteoglycans known to accumulate in CAVD lesions as potential TLR3 ligands. Ligand-receptor interactions were characterized by in silico modeling and verified through immunoprecipitation experiments. Biglycan (Bgn), Tlr3, and IFN-α/β receptor alpha chain (Ifnar1)-deficient mice and a specific zebrafish model were used to study the implication of the biglycan (BGN)-TLR3-IFN axis in both CAVD and bone formation in vivo. Two large-scale cohorts (GERA [Genetic Epidemiology Research on Adult Health and Aging], n=55 192 with 3469 aortic stenosis cases; UK Biobank, n=257 231 with 2213 aortic stenosis cases) were examined for genetic variation at genes implicated in BGN-TLR3-IFN signaling associating with CAVD in humans. RESULTS: Here, we identify TLR3 as a central molecular regulator of calcification in valvular interstitial cells and unravel BGN as a new endogenous agonist of TLR3. Posttranslational BGN maturation by xylosyltransferase 1 (XYLT1) is required for TLR3 activation. Moreover, BGN induces the transdifferentiation of valvular interstitial cells into bone-forming osteoblasts through the TLR3-dependent induction of type I IFNs. It is intriguing that Bgn-/-, Tlr3-/-, and Ifnar1-/- mice are protected against CAVD and display impaired bone formation. Meta-analysis of 2 large-scale cohorts with >300 000 individuals reveals that genetic variation at loci relevant to the XYLT1-BGN-TLR3-interferon-α/β receptor alpha chain (IFNAR) 1 pathway is associated with CAVD in humans. CONCLUSIONS: This study identifies the BGN-TLR3-IFNAR1 axis as an evolutionarily conserved pathway governing calcification of the aortic valve and reveals a potential therapeutic target to prevent CAVD.
引用
- Gollmann-Tepeköylü C, Graber M, Hirsch J, et al. Toll-Like Receptor 3 Mediates Aortic Stenosis Through a Conserved Mechanism of Calcification. Circulation. 2023. PMID: 37013819. doi:10.1161/CIRCULATIONAHA.122.063481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。